Physician profile
Robert E Turner
NPI 1487695474
$10,328.93
in general payments reported to CMS, 2019-2025
51 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,692 · 2020: $1,444 · 2021: $1,737 · 2022: $1,534 · 2023: $1,749 · 2024: $573 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,111.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,043.35 | 2019-2025 | Breztri, Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $990.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $899.92 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $554.94 | 2021-2025 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $554.21 | 2019-2022 | |
| Amgen INC. | $495.23 | 2019-2024 | Otezla, Repatha, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.73 | 2019-2022 | |
| Lilly USA, LLC | $431.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $381.09 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.33 | 2019-2021 | |
| Amarin Pharma, INC. | $308.84 | 2019-2021 | |
| Pfizer INC. | $300.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.87 | 2020-2023 | Glassia |
| Teva Pharmaceuticals USA, INC. | $216.47 | 2020-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.